Log in to search using one of your social media accounts:


Age Does Not Adversely Influence Outcomes among Patients Older than 60 Years Who Undergo Allogeneic Hematopoietic Stem Cell Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome

Allogeneic hematopoietic stem cell transplantation (AHSCT) is a successful treatment modality for AML and MDS. Information on transplant outcomes among older patients is limited because of concern of adverse transplant-related mortality (TRM) and poor overall survival (OS).
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research

Related Links:

More News: Acute Leukemia | Acute Myeloid Leukemia | Leukemia | Lymphoma | Myelodysplastic Syndrome | Myeloma | Stem Cell Therapy | Stem Cells | Transplants